Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  thiotepa
Find trials that include:  Any drugs shown
Results 1-24 of 24 for your search:
Start Over
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 3
Trial IDs: ACNS0334, NCI-2009-00338, CDR0000483683, COG-ACNS0334, NCT00336024
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
Phase: Phase III
Type: Treatment
Age: 10 and under
Trial IDs: ARET0321, NCI-2009-00421, CDR0000573987, COG-ARET0321, NCT00554788
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under at the time of definitive surgery
Trial IDs: ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, NCT00653068
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients with High Risk Malignancies
Phase: Phase II
Type: Treatment
Age: Under 60
Trial IDs: 2008-0363, NCI-2012-01630, NCT00857389
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Combination Chemotherapy with or without Autologous Stem Cell Transplant in Treating Patients with Central Nervous System B-cell Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 to 70
Trial IDs: CALGB 51101, NCI-2012-00110, CDR0000721927, NCT01511562
Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: 0 to 19
Trial IDs: 12-053, NCI-2012-00822, NCT01598025
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 21 and under
Trial IDs: 2660.00, NCI-2013-00958, NCT01858740
Selective Depletion of CD45RA+ Naive T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 14 to 60
Trial IDs: 2684.00, NCI-2014-01301, 2684, NCT02220985
Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Recurrent or Progressive Germ Cell Tumors
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CCI-09-00196, NCI-2013-01195, NCT01270742
Laboratory-Treated Donor Cord Blood Cell Transplant in Treating Patients with Relapsed or Refractory Hematologic Malignancies
Phase: Phase I
Type: Treatment
Age: 1 to 80
Trial IDs: 2010-0658, NCI-2011-03742, NCT01471067
Unrelated Donor Stem Cell Transplant in Treating Patients With Malignant and Non-Malignant Disorders
Phase: No phase specified
Type: Treatment
Age: 0 to 55
Trial IDs: AAAB3095, NCI-2011-00361, NCT01050439
Cyclophosphamide in Treating Patients with Hematological Malignancies after Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 11D.51, NCI-2011-02342, 2010-54, NCT01349101
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid or Central Nervous System Tumors
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 12D.501, NCI-2012-02762, 2012-67, NCT01760655
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Phase: No phase specified
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH 13H11, CMH SCT 0813, SCT 0813 Haplo, NCT02053545
CD34+ Stem Cell Selection in Treating Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Phase: No phase specified
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Start Over